{
 "drug": "Everolimus Tablet",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "11/03/2025",
 "dayN": 295,
 "cat": "Transplant",
 "companies": [
  "Teva Pharmaceuticals USA, Inc.",
  "Endo Pharmaceuticals, Inc.",
  "Mylan Pharmaceuticals Inc., a Viatris Company"
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "03/02/2026",
   "update_type": "New",
   "initial_posting_date": "03/02/2026",
   "package_ndc": "0093-7766-24",
   "generic_name": "Everolimus Tablet",
   "contact_info": "800-545-8800",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "ANDA210050"
    ],
    "brand_name": [
     "EVEROLIMUS"
    ],
    "generic_name": [
     "EVEROLIMUS"
    ],
    "manufacturer_name": [
     "Teva Pharmaceuticals USA, Inc."
    ],
    "product_ndc": [
     "0093-7766",
     "0093-7767",
     "0093-7768",
     "0093-7769"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "EVEROLIMUS"
    ],
    "rxcui": [
     "845507",
     "845515",
     "998189",
     "1119400"
    ],
    "spl_id": [
     "0f7ea770-928b-43b2-8971-849d1d12bbc8"
    ],
    "spl_set_id": [
     "e3bca36b-29ed-4a2b-a1be-a57b6af805f6"
    ],
    "package_ndc": [
     "0093-7766-19",
     "0093-7766-24",
     "0093-7767-19",
     "0093-7767-24",
     "0093-7768-19",
     "0093-7768-24",
     "0093-7769-19",
     "0093-7769-24"
    ],
    "nui": [
     "N0000175605",
     "N0000175076",
     "N0000182141",
     "N0000182137",
     "N0000175625",
     "N0000175624",
     "N0000175550"
    ],
    "pharm_class_epc": [
     "Kinase Inhibitor [EPC]",
     "mTOR Inhibitor Immunosuppressant [EPC]"
    ],
    "pharm_class_moa": [
     "Protein Kinase Inhibitors [MoA]",
     "Cytochrome P450 3A4 Inhibitors [MoA]",
     "Cytochrome P450 2D6 Inhibitors [MoA]",
     "mTOR Inhibitors [MoA]"
    ],
    "pharm_class_pe": [
     "Decreased Immunologic Activity [PE]"
    ],
    "unii": [
     "9HW64Q8G6G"
    ]
   },
   "update_date": "03/02/2026",
   "therapeutic_category": [
    "Transplant"
   ],
   "dosage_form": "Tablet",
   "presentation": "Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24)",
   "company_name": "Teva Pharmaceuticals USA, Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "01/06/2026",
   "update_type": "New",
   "initial_posting_date": "01/06/2026",
   "package_ndc": "49884-119-91",
   "generic_name": "Everolimus Tablet",
   "contact_info": "800-828-9393",
   "related_info": "Discontinuation of the manufacture of the drug",
   "update_date": "01/06/2026",
   "therapeutic_category": [
    "Transplant"
   ],
   "dosage_form": "Tablet",
   "presentation": "Everolimus, Tablet, 2.5 mg (NDC 49884-119-91)",
   "company_name": "Endo Pharmaceuticals, Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "11/03/2025",
   "update_type": "New",
   "initial_posting_date": "11/03/2025",
   "package_ndc": "0378-0005-85",
   "generic_name": "Everolimus Tablet",
   "contact_info": "800-796-9526",
   "related_info": "Discontinuation of the manufacture of the drug",
   "update_date": "11/03/2025",
   "therapeutic_category": [
    "Transplant"
   ],
   "dosage_form": "Tablet",
   "presentation": "Everolimus, Tablet, 2 mg (NDC 0378-0005-85)",
   "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "11/03/2025",
   "update_type": "New",
   "initial_posting_date": "11/03/2025",
   "package_ndc": "0378-0006-85",
   "generic_name": "Everolimus Tablet",
   "contact_info": "800-796-9526",
   "related_info": "Discontinuation of the manufacture of the drug",
   "update_date": "11/03/2025",
   "therapeutic_category": [
    "Transplant"
   ],
   "dosage_form": "Tablet",
   "presentation": "Everolimus, Tablet, 3 mg (NDC 0378-0006-85)",
   "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "01/06/2026",
   "update_type": "New",
   "initial_posting_date": "01/06/2026",
   "package_ndc": "49884-128-91",
   "generic_name": "Everolimus Tablet",
   "contact_info": "800-828-9393",
   "related_info": "Discontinuation of the manufacture of the drug",
   "update_date": "01/06/2026",
   "therapeutic_category": [
    "Transplant"
   ],
   "dosage_form": "Tablet",
   "presentation": "Everolimus, Tablet, 10 mg (NDC 49884-128-91)",
   "company_name": "Endo Pharmaceuticals, Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "03/02/2026",
   "update_type": "New",
   "initial_posting_date": "03/02/2026",
   "package_ndc": "0093-7769-24",
   "generic_name": "Everolimus Tablet",
   "contact_info": "800-545-8800",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "ANDA210050"
    ],
    "brand_name": [
     "EVEROLIMUS"
    ],
    "generic_name": [
     "EVEROLIMUS"
    ],
    "manufacturer_name": [
     "Teva Pharmaceuticals USA, Inc."
    ],
    "product_ndc": [
     "0093-7769",
     "0093-7766",
     "0093-7767",
     "0093-7768"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "EVEROLIMUS"
    ],
    "rxcui": [
     "845507",
     "845515",
     "998189",
     "1119400"
    ],
    "spl_id": [
     "0f7ea770-928b-43b2-8971-849d1d12bbc8"
    ],
    "spl_set_id": [
     "e3bca36b-29ed-4a2b-a1be-a57b6af805f6"
    ],
    "package_ndc": [
     "0093-7766-19",
     "0093-7766-24",
     "0093-7767-19",
     "0093-7767-24",
     "0093-7768-19",
     "0093-7768-24",
     "0093-7769-19",
     "0093-7769-24"
    ],
    "nui": [
     "N0000175605",
     "N0000175076",
     "N0000182141",
     "N0000182137",
     "N0000175625",
     "N0000175624",
     "N0000175550"
    ],
    "pharm_class_epc": [
     "Kinase Inhibitor [EPC]",
     "mTOR Inhibitor Immunosuppressant [EPC]"
    ],
    "pharm_class_moa": [
     "Protein Kinase Inhibitors [MoA]",
     "Cytochrome P450 3A4 Inhibitors [MoA]",
     "Cytochrome P450 2D6 Inhibitors [MoA]",
     "mTOR Inhibitors [MoA]"
    ],
    "pharm_class_pe": [
     "Decreased Immunologic Activity [PE]"
    ],
    "unii": [
     "9HW64Q8G6G"
    ]
   },
   "update_date": "03/02/2026",
   "therapeutic_category": [
    "Transplant"
   ],
   "dosage_form": "Tablet",
   "presentation": "Everolimus, Tablet, 10 mg (NDC 0093-7769-24)",
   "company_name": "Teva Pharmaceuticals USA, Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "01/06/2026",
   "update_type": "New",
   "initial_posting_date": "01/06/2026",
   "package_ndc": "49884-125-91",
   "generic_name": "Everolimus Tablet",
   "contact_info": "800-828-9393",
   "related_info": "Discontinuation of the manufacture of the drug",
   "update_date": "01/06/2026",
   "therapeutic_category": [
    "Transplant"
   ],
   "dosage_form": "Tablet",
   "presentation": "Everolimus, Tablet, 5 mg (NDC 49884-125-91)",
   "company_name": "Endo Pharmaceuticals, Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "11/03/2025",
   "update_type": "New",
   "initial_posting_date": "11/03/2025",
   "package_ndc": "0378-0007-85",
   "generic_name": "Everolimus Tablet",
   "contact_info": "800-796-9526",
   "related_info": "Discontinuation of the manufacture of the drug",
   "update_date": "11/03/2025",
   "therapeutic_category": [
    "Transplant"
   ],
   "dosage_form": "Tablet",
   "presentation": "Everolimus, Tablet, 5 mg (NDC 0378-0007-85)",
   "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "01/06/2026",
   "update_type": "New",
   "initial_posting_date": "01/06/2026",
   "package_ndc": "49884-127-91",
   "generic_name": "Everolimus Tablet",
   "contact_info": "800-828-9393",
   "related_info": "Discontinuation of the manufacture of the drug",
   "update_date": "01/06/2026",
   "therapeutic_category": [
    "Transplant"
   ],
   "dosage_form": "Tablet",
   "presentation": "Everolimus, Tablet, 7.5 mg (NDC 49884-127-91)",
   "company_name": "Endo Pharmaceuticals, Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "03/02/2026",
   "update_type": "New",
   "initial_posting_date": "03/02/2026",
   "package_ndc": "0093-7767-24",
   "generic_name": "Everolimus Tablet",
   "contact_info": "800-545-8800",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "ANDA210050"
    ],
    "brand_name": [
     "EVEROLIMUS"
    ],
    "generic_name": [
     "EVEROLIMUS"
    ],
    "manufacturer_name": [
     "Teva Pharmaceuticals USA, Inc."
    ],
    "product_ndc": [
     "0093-7767",
     "0093-7766",
     "0093-7768",
     "0093-7769"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "EVEROLIMUS"
    ],
    "rxcui": [
     "845507",
     "845515",
     "998189",
     "1119400"
    ],
    "spl_id": [
     "0f7ea770-928b-43b2-8971-849d1d12bbc8"
    ],
    "spl_set_id": [
     "e3bca36b-29ed-4a2b-a1be-a57b6af805f6"
    ],
    "package_ndc": [
     "0093-7766-19",
     "0093-7766-24",
     "0093-7767-19",
     "0093-7767-24",
     "0093-7768-19",
     "0093-7768-24",
     "0093-7769-19",
     "0093-7769-24"
    ],
    "nui": [
     "N0000175605",
     "N0000175076",
     "N0000182141",
     "N0000182137",
     "N0000175625",
     "N0000175624",
     "N0000175550"
    ],
    "pharm_class_epc": [
     "Kinase Inhibitor [EPC]",
     "mTOR Inhibitor Immunosuppressant [EPC]"
    ],
    "pharm_class_moa": [
     "Protein Kinase Inhibitors [MoA]",
     "Cytochrome P450 3A4 Inhibitors [MoA]",
     "Cytochrome P450 2D6 Inhibitors [MoA]",
     "mTOR Inhibitors [MoA]"
    ],
    "pharm_class_pe": [
     "Decreased Immunologic Activity [PE]"
    ],
    "unii": [
     "9HW64Q8G6G"
    ]
   },
   "update_date": "03/02/2026",
   "therapeutic_category": [
    "Transplant"
   ],
   "dosage_form": "Tablet",
   "presentation": "Everolimus, Tablet, 5 mg (NDC 0093-7767-24)",
   "company_name": "Teva Pharmaceuticals USA, Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "03/02/2026",
   "update_type": "New",
   "initial_posting_date": "03/02/2026",
   "package_ndc": "0093-7768-24",
   "generic_name": "Everolimus Tablet",
   "contact_info": "800-545-8800",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "ANDA210050"
    ],
    "brand_name": [
     "EVEROLIMUS"
    ],
    "generic_name": [
     "EVEROLIMUS"
    ],
    "manufacturer_name": [
     "Teva Pharmaceuticals USA, Inc."
    ],
    "product_ndc": [
     "0093-7768",
     "0093-7766",
     "0093-7767",
     "0093-7769"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "EVEROLIMUS"
    ],
    "rxcui": [
     "845507",
     "845515",
     "998189",
     "1119400"
    ],
    "spl_id": [
     "0f7ea770-928b-43b2-8971-849d1d12bbc8"
    ],
    "spl_set_id": [
     "e3bca36b-29ed-4a2b-a1be-a57b6af805f6"
    ],
    "package_ndc": [
     "0093-7766-19",
     "0093-7766-24",
     "0093-7767-19",
     "0093-7767-24",
     "0093-7768-19",
     "0093-7768-24",
     "0093-7769-19",
     "0093-7769-24"
    ],
    "nui": [
     "N0000175605",
     "N0000175076",
     "N0000182141",
     "N0000182137",
     "N0000175625",
     "N0000175624",
     "N0000175550"
    ],
    "pharm_class_epc": [
     "Kinase Inhibitor [EPC]",
     "mTOR Inhibitor Immunosuppressant [EPC]"
    ],
    "pharm_class_moa": [
     "Protein Kinase Inhibitors [MoA]",
     "Cytochrome P450 3A4 Inhibitors [MoA]",
     "Cytochrome P450 2D6 Inhibitors [MoA]",
     "mTOR Inhibitors [MoA]"
    ],
    "pharm_class_pe": [
     "Decreased Immunologic Activity [PE]"
    ],
    "unii": [
     "9HW64Q8G6G"
    ]
   },
   "update_date": "03/02/2026",
   "therapeutic_category": [
    "Transplant"
   ],
   "dosage_form": "Tablet",
   "presentation": "Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24)",
   "company_name": "Teva Pharmaceuticals USA, Inc.",
   "status": "To Be Discontinued"
  }
 ]
}